Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMatthias Tschoep, MD
About
Research
Publications
2026
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
Liskiewicz D, Novikoff A, Khalil A, Akindehin S, Campbell J, Candela P, Castelino R, Coupland C, Culot M, Dodson W, Douros J, Embring H, Feuchtinger A, Finan B, Garcia-Caceres C, Gao X, Gosselet F, Grandl G, Gutgesell R, Haas D, Jastroch M, Karaoglu E, Kakimoto P, Kaltenbach A, Keuper M, Kusminski C, Leander D, Liskiewicz A, Liu X, Maity-Kumar G, Martinez S, Mowery S, Nogueiras R, Paisley M, Perez-Tilve D, Petersen P, Pfluger P, Prakash S, Steffens S, Cebrian-Serrano A, Tost M, Wean J, Weber C, Yoshida J, Gerhart-Hines Z, Horvath T, Scherer P, Seeley R, DiMarchi R, Tschöp M, Krahmer N, Knerr P, Müller T. GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature 2026, 1-10. PMID: 42056522, DOI: 10.1038/s41586-026-10427-5.Peer-Reviewed Original ResearchCo-agonismAnti-inflammatory effectsMetabolic efficacyPharmacological inhibitionGLP-1RIncretin receptor signalingReceptor knockout miceMetabolic actionsPhase 3 trialClinical phase 3 trialManagement of obesityTreatment of obesityBlood glucose-lowering effectGlucose-lowering effectStimulation of insulin secretionBody weight-reducingInsulin-resistant miceFood intakeMetabolic dysfunctionReceptor signalingEffective drugsInsulin sensitivityPPAR actionMiceTargeted deliveryGIPR:GCGR co-agonism restores normal weight in obese rodents
Perez-Tilve D, Zhang F, Zhang Y, Lohman K, Sorrell J, Vick A, Müller T, Tschöp M, DiMarchi R. GIPR:GCGR co-agonism restores normal weight in obese rodents. Molecular Metabolism 2026, 108: 102365. PMID: 41997446, PMCID: PMC13141540, DOI: 10.1016/j.molmet.2026.102365.Peer-Reviewed Original ResearchGlucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
Nauck M, Tuttle K, Tschöp M, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet 2026, 407: 892-908. PMID: 41547366, DOI: 10.1016/s0140-6736(25)02105-1.Peer-Reviewed Original ResearchConceptsGLP-1 receptor agonistsGlucose-dependent insulinotropic polypeptideReceptor agonistsGLP-1Type 2 diabetesHeart failureDual glucose-dependent insulinotropic polypeptideEstimated glomerular filtration rateDose-escalation regimensObstructive sleep apnoeaAdverse gastrointestinal eventsGlomerular filtration ratePrevention of fibrosisPrevention of type 2 diabetesAdverse cardiovascular eventsObesity-related conditionsClinical development programmeTreatment of obesityRegression of steatosisEvidence of efficacySleep apnoeaGastrointestinal eventsSymptomatic improvementOral treatmentCardiovascular events
2025
Publisher Correction: GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
Gutgesell R, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros J, Knerr P, Finan B, DiMarchi R, Sloop K, Samms R, Theis F, Tschöp M, Müller T. Publisher Correction: GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nature Metabolism 2025, 7: 1299-1299. PMID: 40360757, PMCID: PMC12198006, DOI: 10.1038/s42255-025-01308-8.Peer-Reviewed Original ResearchGIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
Gutgesell R, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu X, Garcia-Caceres C, Cebrian-Serrano A, Douros J, Knerr P, Finan B, DiMarchi R, Sloop K, Samms R, Theis F, Tschöp M, Müller T. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nature Metabolism 2025, 7: 1282-1298. PMID: 40301583, PMCID: PMC12198009, DOI: 10.1038/s42255-025-01294-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptide receptorFood intake effectsGLP-1R signalingGLP-1RBody weightFood intakeNervous systemDorsal vagal complexBody weight lossGLP-1R agonismCentral nervous systemPeripheral nervous systemGABAergic neuronsVagal complexMale miceSingle-nucleus RNA sequencingSynaptic plasticityPolypeptide receptorWeight lossMiceAgonismNeuronsAntagonismGIPRRegulated genesEstrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism
Coupland C, Sun N, Khalil A, Karaoglu Ö, Liskiewicz A, Liskiewicz D, Grandl G, Akindehin S, Maity G, Yang B, Finan B, Knerr P, Douros J, Walch A, DiMarchi R, Tschöp M, Müller T, Novikoff A. Estrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism. Molecular Metabolism 2025, 96: 102136. PMID: 40204014, PMCID: PMC12032945, DOI: 10.1016/j.molmet.2025.102136.Peer-Reviewed Original ResearchA once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
Finan B, Douros J, Goldwater R, Hansen A, Hjerpsted J, Hjøllund K, Kankam M, Knerr P, Konkar A, Mowery S, Müller T, Nielsen J, Nygård S, Perez-Tilve D, Raun K, Yang B, Tschöp M, DiMarchi R. A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans. Molecular Metabolism 2025, 96: 102129. PMID: 40139439, PMCID: PMC12051155, DOI: 10.1016/j.molmet.2025.102129.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic peptide receptorTri-agonistsClinical developmentGlycemic controlSubstantial body weight lossSignificant body weight reductionBody weight reductionBody weight lossLowered body weightDose-dependent mannerTreatment cohortsNon-human primatesObesity treatmentObese micePeptide receptorGLP-1RHuman participantsHeart rateWeight lossBody weightGlucagon receptorObesityWeight reductionReceptorsMode of actionRegulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments
Becker M, Kälin S, Neubig A, Lauber M, Opaleva D, Hipp H, Salb V, Ott V, Legutko B, Kälin R, Hippich M, Scherm M, Nascimento L, Serr I, Hosp F, Nikolaev A, Mohebiany A, Krueger M, Flachmeyer B, Pfaffl M, Haase B, Yi C, Dietzen S, Bopp T, Woods S, Waisman A, Weigmann B, Mann M, Tschöp M, Daniel C. Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments. Nature Communications 2025, 16: 2744. PMID: 40113758, PMCID: PMC11926360, DOI: 10.1038/s41467-025-57918-z.Peer-Reviewed Original ResearchGlucose-dependent insulinotropic polypeptide (GIP)
Müller T, Adriaenssens A, Ahrén B, Blüher M, Birkenfeld A, Campbell J, Coghlan M, D'Alessio D, Deacon C, DelPrato S, Douros J, Drucker D, Figueredo Burgos N, Flatt P, Finan B, Gimeno R, Gribble F, Hayes M, Hölscher C, Holst J, Knerr P, Knop F, Kusminski C, Liskiewicz A, Mabilleau G, Mowery S, Nauck M, Novikoff A, Reimann F, Roberts A, Rosenkilde M, Samms R, Scherer P, Seeley R, Sloop K, Wolfrum C, Wootten D, DiMarchi R, Tschöp M. Glucose-dependent insulinotropic polypeptide (GIP). Molecular Metabolism 2025, 95: 102118. PMID: 40024571, PMCID: PMC11931254, DOI: 10.1016/j.molmet.2025.102118.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideDevelopment of pharmacotherapiesGlucagon-like peptide 1Drug-induced nauseaBeneficial effectsMaintenance of glucose toleranceGIPR agonismGlucose toleranceGLP-1Incretin hormonesMetabolic effectsPharmacological demonstrationTherapeutic implicationsHealthy humansPleiotropic hormoneObesityPeptide 1IncretinNeurodegenerative disordersDiabetesSignal modificationEndocrine pancreasGIPRHormoneBiologyDefinition and diagnostic criteria of clinical obesity
Rubino F, Cummings D, Eckel R, Cohen R, Wilding J, Brown W, Stanford F, Batterham R, Farooqi I, Farpour-Lambert N, le Roux C, Sattar N, Baur L, Morrison K, Misra A, Kadowaki T, Tham K, Sumithran P, Garvey W, Kirwan J, Fernández-Real J, Corkey B, Toplak H, Kokkinos A, Kushner R, Branca F, Valabhji J, Blüher M, Bornstein S, Grill H, Ravussin E, Gregg E, Al Busaidi N, Alfaris N, Al Ozairi E, Carlsson L, Clément K, Després J, Dixon J, Galea G, Kaplan L, Laferrère B, Laville M, Lim S, Luna Fuentes J, Mooney V, Nadglowski J, Urudinachi A, Olszanecka-Glinianowicz M, Pan A, Pattou F, Schauer P, Tschöp M, van der Merwe M, Vettor R, Mingrone G. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology 2025, 13: 221-262. PMID: 39824205, PMCID: PMC11870235, DOI: 10.1016/s2213-8587(24)00316-4.Peer-Reviewed Original ResearchPublic health strategiesExcess adiposityEvidence-based treatmentsClinical obesityPatient perspectiveHealth strategiesMedical specialtiesMeasure of health riskBMI-based measuresEffects of excess adiposityExperience of obesityNon-communicable diseasesMeasures of healthHealth-care professionalsLimitation of daily activitiesConsensus development processIssue of obesityMeasures of body fatPrevalence of obesityLife-threatening illnessIndividual health risksPatient advocacy groupsPopulation levelEnd-organ damageHighest level of consensus